Cargando…

A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

Epigenetic events and genetic alterations under the control of the tumor microenvironment potentially mediate tumor induced angiogenesis involved in soft tissue sarcoma (STS) metastasis. Addition of antiangiogenic agent, such as bevacizumab, to standard chemotherapy in treatment of sarcoma has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monga, Varun, Swami, Umang, Tanas, Munir, Bossler, Aaron, Mott, Sarah L., Smith, Brian J., Milhem, Mohammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836085/ https://www.ncbi.nlm.nih.gov/pubmed/29462961 http://dx.doi.org/10.3390/cancers10020053

Ejemplares similares

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
por: Swami, Umang, et al.
Publicado: (2019)

Patient reported quality of life in young adults with sarcoma receiving care at a sarcoma center
por: Day, Jonathan R., et al.
Publicado: (2022)

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
por: Swami, Umang, et al.
Publicado: (2020)

Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study
por: Zakharia, Yousef, et al.
Publicado: (2017)

Photodynamic Therapy Using Hippo Pathway Inhibitor Verteporfin: A Potential Dual Mechanistic Approach in Treatment of Soft Tissue Sarcomas
por: Rytlewski, Jeffrey D., et al.
Publicado: (2021)

Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
por: Rytlewski, Jeff, et al.
Publicado: (2021)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

Effects of the Histone Deacetylase Inhibitor Valproic Acid on Human Pericytes In Vitro
por: Karén, Jakob, et al.
Publicado: (2011)

Effects of histone deacetylase inhibitor valproic acid on skeletal myocyte development
por: Li, Qiao, et al.
Publicado: (2014)

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy
por: Rieth, John M., et al.
Publicado: (2021)

CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
por: Kohlmeyer, Jordan L, et al.
Publicado: (2020)

Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples
por: Berendsen, Sharon, et al.
Publicado: (2019)

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
por: Rytlewski, Jeff, et al.
Publicado: (2022)

Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells
por: Stockhausen, M-T, et al.
Publicado: (2005)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
por: Swami, Umang, et al.
Publicado: (2019)

Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro
por: ZHOU, YONG, et al.
Publicado: (2014)

Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2012)

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial
por: Monga, Varun, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

Migration, Proliferation, and Differentiation of Cord Blood Mesenchymal Stromal Cells Treated with Histone Deacetylase Inhibitor Valproic Acid
por: Marquez-Curtis, Leah A., et al.
Publicado: (2014)

HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice
por: Scholz, Beatrix, et al.
Publicado: (2019)

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
por: Laengle, Johannes, et al.
Publicado: (2020)

Histone deacetylase 2 inhibitor valproic acid attenuates bisphenol A-induced liver pathology in male mice
por: Al-Griw, Mohamed A., et al.
Publicado: (2022)

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
por: Fredly, Hanne, et al.
Publicado: (2013)

Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
por: Greco, Austin, et al.
Publicado: (2019)

Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021)

A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
por: Rocca, A, et al.
Publicado: (2009)

Histone Deacetylase Inhibitor Valproic Acid Promotes the Differentiation of Human Induced Pluripotent Stem Cells into Hepatocyte-Like Cells
por: Kondo, Yuki, et al.
Publicado: (2014)

Valproic Acid as a Potential Inhibitor of Plasmodium falciparum Histone Deacetylase 1 (PfHDAC1): An in Silico Approach
por: Elbadawi, Mohamed A. Abdallah, et al.
Publicado: (2015)

Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts
por: He, Yingzi, et al.
Publicado: (2014)

The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells
por: Cerna, Tereza, et al.
Publicado: (2018)

Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells
por: Shyu, Yueh-Ming, et al.
Publicado: (2021)

Non-Conventional Treatments for Conventional Chondrosarcoma
por: Monga, Varun, et al.
Publicado: (2020)

Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells
por: Dejligbjerg, Marielle, et al.
Publicado: (2008)

Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells
por: Biermann, Julia, et al.
Publicado: (2011)

Differentiation of rat adipose tissue-derived stem cells into neuron-like cells by valproic acid, a histone deacetylase inhibitor
por: Okubo, Takumi, et al.
Publicado: (2015)

Protective Effects of Valproic Acid, a Histone Deacetylase Inhibitor, against Hyperoxic Lung Injury in a Neonatal Rat Model
por: Cetinkaya, Merih, et al.
Publicado: (2015)

The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF-κB pathway in multiple myeloma cells
por: Liu, Zhaoyun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pith8s5am4nqeqaa6g5dam878k